ALDX_OUT_1 [2025-04-04 10:50:43 -0400] 3276 Bytes | 872 tokens | Cum: 872 tkns (10.90% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Aldeyra Therapeutics (ALDX) which is at 1.7991 up from 1.42. So, I pulled together a bunch of data for you to look over real fast. It's still early, 10:50:42 AM on Fri Apr 04, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Aldeyra Therapeutics (ALDX)
IPO: 2014-05-02 (10 Years Ago)
Market Cap: $100,011,995
Shares Outstanding: 59,710,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Here’s the first list of news for Aldeyra Therapeutics:

C1 - Apr-03-25 10:24AM - Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter
C2 - Apr-03-25 10:24AM 08:00AM - Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
C3 - Mar-10-25 07:00AM - Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference
C4 - Feb-05-25 03:24AM - Aldeyra Therapeutics, Inc. (ALDX) Notice: Grabar Law Office Is Investigating Claims for Long-Term Shareholders
C5 - Feb-04-25 07:00AM - Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
C6 - Jan-20-25 03:28PM - Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman's Long-Term Stock Picks?
C7 - Dec-09-24 10:05AM - Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?
C8 - Dec-02-24 07:00AM - Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Aldeyra Therapeutics (ALDX).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

ALDX_OUT_3 [2025-04-04 10:50:47 -0400] 1098 Bytes | 290 tokens | Cum: 1165 tkns (14.56% of 8k)
==========================================================================

Showing C1 (chunk 1 of 2): C1:
**Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter**
Date: Apr-03-25 10:24AM
Source: (Investopedia)
URL: https://www.investopedia.com/aldeyra-therapeutics-stock-craters-to-all-time-low-on-fda-letter-dry-eye-disease-11708268

Shares of Aldeyra Therapeutics (ALDX) plummeted nearly 75% to an all-time low Thursday morning after theFood and Drug Administration (FDA)said the company's dry eye disease drug has not proven to be effective in enough studies.

The developmental drug company said that it received a letter from the FDA responding to its new drug application (NDA) for reproxalap, a treatment for dry eye disease.

The drug has "failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes," the FDA wrote, Aldeyra said. The agency told the firm that it needs to prove the drug's effectiveness in at least on

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALDX_OUT_5 [2025-04-04 10:50:48 -0400] 912 Bytes | 284 tokens | Cum: 1523 tkns (19.04% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-04T13:41:50Z - Aldeyra Therapeutics (ALDX) PT Lowered to $6 at Jefferies...
A2 - 2025-04-04T10:43:38Z - H.C. Wainwright Reiterates Buy Rating on Aldeyra Therapeutics (ALDX)...
A3 - 2025-04-03T22:34:00Z - US Trade Policies Ignite a Stock Market Meltdown...
A4 - 2025-04-03T21:05:48Z - 12 Health Care Stocks Moving In Thursday's After-Market Session - Aldeyra Therapeutics (NASDAQ:ALDX)...
A5 - 2025-04-03T21:03:28Z - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutic...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ALDX_OUT_7 [2025-04-04 10:50:51 -0400] 821 Bytes | 256 tokens | Cum: 1781 tkns (22.26% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
**Aldeyra Therapeutics (ALDX) PT Lowered to $6 at Jefferies**Date: 2025-04-04Source: {'uri': 'streetinsider.com', 'dataType': 'news', 'title': 'StreetInsider.com'}URL: https://www.streetinsider.com/Analyst+Comments/Aldeyra+Therapeutics+%28ALDX%29+PT+Lowered+to+%246+at+Jefferies/24601484.htmlJefferies analyst Kelly Shi lowered the price target on Aldeyra Therapeutics (NASDAQ: ALDX) to $6.00 (from $8.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALDX_OUT_9 [2025-04-04 10:50:52 -0400] 818 Bytes | 284 tokens | Cum: 2121 tkns (26.51% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-06-02T10:49:06Z - Wall Street Breakfast: The Week Ahead
B2 - 2024-05-14T13:40:10Z - Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
B3 - 2024-04-22T13:40:10Z - Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
B4 - 2024-04-06T10:37:00Z - Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
B5 - 2024-04-05T13:40:12Z - Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
B6 - 2024-04-04T10:23:06Z - Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALDX_OUT_11 [2025-04-04 10:50:54 -0400] 466 Bytes | 131 tokens | Cum: 2254 tkns (28.18% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Wall Street Breakfast: The Week Ahead**Date: Unknown DateSource: Unknown SourceURL: https://seekingalpha.com/article/4696976-wall-street-breakfast-week-aheadRead about the upcoming Wall Street events, earnings reports, conferences, and IPOs for the week ahead.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALDX_OUT_13 [2025-04-04 10:50:55 -0400] 1105 Bytes | 302 tokens | Cum: 2599 tkns (32.49% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-03 8-K Item7.01. Regulation FD Disclosure.

As reported under Item 8.01 of this Curr Report on Form 8-K, on April 3, 2025, Aldeyra Therapeutics, Inc. (Aldeyra or the Company) issued a press release (the Press Release) to provide a regulatory update regarding reproxalap, an investiga...

S4 - 2025-02-28 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing at the...

S5 - 2024-11-18 8-K Item1.01. Entry into a Material Definitive Agrmt.

On November 15, 2024, Aldeyra Therapeutics, Inc. (the Company) entered into the Extension Side Letter (the Extension Letter) with AbbVie Inc. (AbbVie), which amended certain terms of the Exclusive Option Agrmt (the Optio...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALDX_OUT_15 [2025-04-04 10:50:56 -0400] 1098 Bytes | 230 tokens | Cum: 2831 tkns (35.39% of 8k)
==========================================================================

Showing S4 (chunk 1 of 6): S4:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing at the end of this annual report on Form 10-K. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, uncertainties and assumptions. You should read the Risk Factors and Special Note Regarding Forward-Looking Statements sections of this annual report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and anal

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALDX_OUT_17 [2025-04-04 10:51:09 -0400] 5045 Bytes | 1397 tokens | Cum: 4230 tkns (52.88% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+---------------------+
| Volume: 5,287,892 | Perf Month: -72.50% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+-------------------------+---------------------+
| Avg Volume: 976.99K | Perf Quarter: -66.86% | Short Float: 6.89% | ROE: -58.54% |
+---------------------+-----------------------+-------------------------+---------------------+
| Rel Volume: 25.98 | Index: RUT | Short Ratio: 4.09 | ROI: -64.94% |
+---------------------+-----------------------+-------------------------+---------------------+
| RSI (14): 20.34 | Market Cap: 103.30M | Short Interest: 3.99M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+---------------------+
| ATR (14): 0.78 | Shs Outstand: 59.65M | Beta: 1.11 | EPS Surprise: 0.49% |
+---------------------+-----------------------+-------------------------+---------------------+
| SMA20: -71.00% | Shs Float: 57.98M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-------------------------+---------------------+
| SMA50: -71.02% | Inst Own: 62.88% | Sales past 5Y: 0.00% | Earnings: Mar 06 |
+---------------------+-----------------------+-------------------------+---------------------+
| SMA200: -66.36% | Insider Own: 2.90% | Employees: 9 | |
+---------------------+-----------------------+-------------------------+---------------------+
| Perf Week: -74.06% | Insider Trans: 0.05% | Debt/Eq: 0.22 | |
+---------------------+-----------------------+-------------------------+---------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: Aldeyra Therapeutics, Inc. (ALDX) by Machatha Stephen (Chief Development Officer) on 2025-03-04
- Stock Option (right to buy): 202427 shares at $0 (D)

Inside Trans: Aldeyra Therapeutics, Inc. (ALDX) by Brady Todd C (President and CEO) on 2025-03-04
- Stock Option (right to buy): 809710 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -44795639.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.77
Average Volume: 2101296.7
30-Day High: 6.98
30-Day Low: 1.42

[Detailed Financials: Q3 2024]
- Total Assets: $117,319,352.0
- Total Liabilities: $32,223,648.0
- Total Equity: $85,095,704.0
- Current Assets: $116,720,763.0
- Current Liabilities: $17,153,414.0

[Income Statement: Q3 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.25

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-2,909,694.0

[Detailed Financials: Q2 2024]
- Total Assets: $126,043,834.0
- Total Liabilities: $27,733,495.0
- Total Equity: $98,310,339.0
- Current Assets: $125,649,519.0
- Current Liabilities: $27,594,602.0

[Income Statement: Q2 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.28

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-31,462,177.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

ALDX_OUT_19 [2025-04-04 10:51:11 -0400] 687 Bytes | 169 tokens | Cum: 4708 tkns (58.85% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

ALDX_IN_21 [2025-04-04 10:51:11 -0400] 126 Bytes | 29 tokens | Cum: 4767 tkns (59.59% of 8k)
==========================================================================

====================================
[2025-04-04 10:51:11] # Analysis Completed
Elapsed Time: 29.10 seconds